Background: It is urgent to make EBTs for military personnel readily accessible in order to meet the growing demand for effective and efficient treatment for PTSD in a timely manner. Effective EBTs for PTSD are available, but barriers to accessing care can deter military personnel from accessing care. Web-treatments represent an innovative way to overcome these barriers. The efficacy of previously developed web-treatments for PTSD appear promising, however, they are not based on treatment protocols with strong empirical support for their efficacy. Hence, it cannot be discerned whether the outcomes associated with existing web-treatments are due to the new intervention or to factors associated with the use of the Internet to deliver the treatment. No study to date has examined web-treatment of PTSD using a well-established treatment program. An important unanswered question is whether moving from the traditional, costly, access-limiting, therapist-delivered format of an effective treatment to a more accessible, cost-effective, web-format will impact treatment efficacy. In addition, based on evidence showing a link between neurosteroids and psychopathology and a role in PTSD treatment response, an add-on biomarkers study was funded that examines the role of candidate biomarkers \[endogenous glucocorticoids and neurosteroids, i.e. cortisol, allopregnanolone (ALLO) and metabolites, and dehydroepiandrosterone (DHEA/DHEAS)\] as: a) predictors of treatment response, and b) indices of therapeutic change during PTSD treatment.

Objective/Hypotheses: To eliminate the confound inherent in changing simultaneously both the treatment program and the mode of delivery, the investigators propose to develop a web-version of PE, "Web-PE", and compare its efficacy to Present Centered Treatment (PCT), an active control comparison. The investigators hypothesize that Web-PE will be a more efficacious in reducing PTSD severity than PCT among military personnel returned from deployments in Afghanistan and Iraq at post-treatment and 3- and 6-months after treatment completion. In addition, the investigators expect that changes cortisol and neurosteriods will track symptom change.

Specific Aims: The first aim is to develop a Web-PE program that will receive high ratings of ease of use, acceptability, comprehension of program content and functionality, and overall satisfaction by military personnel with PTSD symptoms and an advisory board of eight experts in PE and the treatment PTSD in the military. The second aim is to examine the efficacy of Web-PE by comparing it to therapist-delivered PCT on the following outcomes: 1) Change in PTSD severity and diagnostic status from pre- to post-treatment; 2) Change in symptoms of depression, anger, and other frequently co-occurring problems from pre- to post-treatment. The biological aims of the study include: 1) To identify specific neuroendocrine and neurosteroid changes that "track" Posttraumatic Stress Disorder (PTSD) symptom change over the course of effective treatment and 2) to determine the specificity of Prolonged Exposure (PE) -induced neuroendocrine/neurosteroid changes by directly comparing patterns of change during PE to those during Present Centered Therapy (PCT).

Study Design: During Phase I (months 0-9), the investigators will develop and demonstrate the feasibility of the Web-PE program by piloting it with 10 military personnel with PTSD or subclinical PTSD and by members of the expert advisory board. During Phase II (months 9-36), the investigators will conduct an RCT comparing the efficacy of Web-PE with therapist-delivered PCT on measures of PTSD symptom severity and related psychopathology with 160 OIF/OEF active duty military personnel with PTSD. Cortisol Awakening Response collected at home on the three mornings prior to the research sessions that occur at baseline, week 4, one and three months follow-up. Script driven imagery saliva collection for salivary cortisol in response to the general environment and specific trauma cues at baseline, week 4, and one and three months follow-up. Serum neurosteriods (allopregnanolone, pregnenolone, pregnanolone, androsterone, DHEA) at baseline, week 4 and 1 month follow-up of treatment.

Relevance: Untreated PTSD becomes a chronic disorder, leaving military service-men and -women less effective or unable to perform their military duties, more likely to have comorbid mental and physical health problems as well as difficulties in daily functioning (Vasterling et al., 2007). The proposed Web-PE program can function as the first step in a step care model. As such it is expected to greatly facilitate the dissemination of EBT to those in need by capitalizing on the greater accessibility, cost-effectiveness, and anonymity that is afforded by Internet. Thus, the proposed study directly targets the MOM/JPC interest in research aim at developing and validating novel EBTs that exploit innovative telemedicine technologies. Because Web-PE could be accessed at home, the proposed study is also relevant to the MOM/ JPC interest in strategies to reduce the stigma associated with PTSD treatment. Integrating affective neuroscience methods into an RCT can make each study more informative, effective, and less expensive than two independent studies. Neurobiological studies of PTSD have linked specific candidate biomarkers \[endogenous glucocorticoids and neurosteroids, i.e. cortisol, allopregnanolone (ALLO) and metabolites, and dehydroepiandrosterone (DHEA/DHEAS)\] to PTSD severity and potentially to treatment response. Identifying the mechanisms involved in treatment response can assist in improving therapeutic techniques by targeting specific neurobiological processes involved.

This study is affiliated with the South Texas Research Organizational Network Guiding Studies on Trauma and Resilience (STRONG STAR) (Consortium Director: Alan L. Peterson, Ph.D., ABPP, Professor, Behavioral Wellness Center for Clinical Trials, Department of Psychiatry-Mail Code 7792, University of Texas Health Science Center at San Antonio (UTHSCSA), 7703 Floyd Curl Drive, San Antonio, TX 78229-3900). The Overall PIs for this study are Carmen P. McLean, Ph.D. of the Center for the Treatment and Study of Anxiety at the University of Pennsylvania and, for the biological measures portion of the study, Sheila Rauch, Ph.D., ABPP of Emory University. The PI for this study at the University of Texas Health Science Center at San Antonio (UTHSCSA) is Alan Peterson, Ph.D., ABPP, Department of Psychiatry, Division of Behavioral Medicine. The on-site PI is COL Jeffrey Yarvis, Ph.D.,Chief, Soldier Behavioral Health/Outpatient Psychiatry, Carl R. Darnall Army Medical Center, 36000 Darnall Loop, Fort Hood, TX, 76544. The study will be conducted at Fort Hood, Texas.